Skip to content
AIPressRoom

FundingHealthcare & Biotech

Science Corporation Lands $400M to Advance Brain-Computer Interface

Science Corporation raised $400M Series D to advance its brain-computer interface technology and expand vision restoration devices.

Science Corporation raises $400M

The big picture: Science Corporation, the medical technology startup founded by former Neuralink president Max Hodak, has closed a $400 million Series D funding round, valuing the company at $3.5 billion.

Why it matters:

  • Restoring Vision: Science Corporation’s first product, PRIMA, is an implantable chip designed to help patients with age-related macular degeneration recover vision, already approved in Europe and undergoing trials for Stargardt disease.
  • US Market Entry: The new funding will support the company’s efforts to bring PRIMA to the United States via the FDA’s Humanitarian Device Exemption, targeting rare conditions.
  • Future of Neurotech: Beyond vision, Science Corporation’s long-term ambition is to develop bio-hybrid sensors that directly connect to the human brain, potentially offering treatments for conditions like Parkinson’s disease.

How it works:

  • PRIMA Device: The company’s initial offering is a wearable and implantable chip that aids in vision recovery for specific degenerative eye conditions, currently available in Germany.
  • FDA Pathway: Science Corporation is leveraging the FDA’s Humanitarian Device Exemption, a regulatory path for experimental medical technologies treating rare diseases, to enter the US market.
  • Bio-Hybrid Sensors: The core of Science Corporation’s future technology involves creating sensors from a combination of cultured neurons and silicon, designed for direct interaction with the human brain.

The catch: Developing implantable brain-computer interfaces is a highly complex and regulated field, requiring extensive clinical trials and navigating significant ethical considerations. While the vision restoration device is a tangible first step, the broader ambition of direct brain connection faces substantial technical and regulatory hurdles, alongside competition from other well-funded neurotechnology ventures.

Key Facts

  • Company: Science Corporation
  • Amount: $400M
  • Round: Series D
  • Investors: Khosla Ventures, the Ackman Oxman Institute, Tenet Healthcare, 885 Capital, Y Combinator, PLC Neurotech
  • Founder: Max Hodak
  • Valuation: $3,500,000,000
  • Announced: 2026-11-17
  • Sector: Neurotechnology, Brain-Computer Interface

AIPressRoom Weekly

Every round we reported this week, the people behind the companies, and the events coming up. One email, every Tuesday.

More in Healthcare & Biotech

All